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Clinical Trial Results Summary for Laypersons ± a 
user testing study 
 
ABSTRACT 
Background: The objective was to aSSO\µXVHUWHVWLQJ¶WRmaximise readability and 
acceptability (for all education levels) of a Clinical Trial Results Laypersons 
Summary ± a new European requirement for trials of new medicines.  
Methods: µUser testing¶ using mixed methods (questionnaire and semi-structured 
interview) was used to assess document performance ² can people find and 
understand key points? Findings were used to improve document content and 
design, which was then tested again. Participants were members of the UK public 
with a range of levels of health literacy and a higher education group. As the 
summaries will be made available on a website, participants accessed the 
summary on screen. In Round 1 we tested 12 points of information. In Round 2 a 
revised summary addressing the findings of Round 1 was tested. A third final version 
was then prepared.   
Results: In Round 1, 2 of the 12 points of information did not reach the target and 
semi-structured interviews raised further issues related to both format and content 
(participants being distracted by some technical explanations and the inability to find 
or understand the two main purposes of the study. . These findings informed 
revisions for the version tested in Round 2, where 2 different points did not reach the 
target. One of these points focused on inclusion criteria relating to duration of 
seasonal allergies, the other related to how the researchers found out about 
SDUWLFLSDQWV¶V\PSWRPVThe identified problems in both rounds were addressed and 
reflected in the final version.  Despite improvements, participants did not consistently 
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understand the summaries were intended for the general public, or that results of 
single trials should only be interpreted in the context of additional trials. All readers, 
including those with higher education, found the clear and straight forward language 
acceptable. 
Conclusions: Applying µXVHUWHVWLQJ¶UHVXOWHGLQa largely health literate summary 
suitable for people across a range of backgrounds.   
Key words: 
x Clinical trial 
x Lay summary 
x User testing 
x Readability 
x Health literacy 
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INTRODUCTION  
In Europe, clinical trial sponsors will soon be required by the new EU Clinical Trials 
Regulation (1) to publish a public summary of clinical trial results within one year of 
the trial ending. The purpose of the public summary is to provide information on the 
background of the trial, the processes, study population, trial medicines used and 
any side effects, as well as the overall results (2). It is intended to be read by the 
general public. This regulation only applies in Europe, however in some 
countries such summaries are available for people who have taken part in a 
trial. 
The Regulation provided little detail on how the summaries should be written and 
presented ± only WKHµHOHPHQWV¶WKDWPXVWEHLQFOXGHGLQthe summaries - which have 
been interpreted as headings (see Table 1).  
Subsequently, in 2016, a consultation from the European Commission detailed 
recommendations from the ³(xpert Group on Clinical Trials´ for the implementation 
of the regulation. (3) This GUDIWJXLGDQFHQRWHGWKDWµwhere feasible, sponsors should 
consider testing the readability of an initial version of the study results summary with 
a small number of people who represent the target population¶However, it appears 
that no such testing has been applied to the text, the guidance itself recommends for 
inclusion in the summaries.  
(Table 1 Here) 
 
As a result, we decided to test the readability of a proposed summary consistent with 
the EU guidance EXWZLWKOD\IULHQGO\KHDGLQJVUHSODFLQJWKHRULJLQDOµHOHPHQWV¶). We 
used WKHSURFHVVIRUDVVHVVLQJWKHUHDGDELOLW\RIGRFXPHQWVFDOOHGµXVHUWHVWLQJ¶
This method, GHYHORSHGLQWKHVLQ$XVWUDOLDLVDW\SHRI³SHUIRUPDQFH-based 
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WHVWLQJ´ (4). It simultaneously tests the usability of both content and structure of a 
document with potential users. It is routinely used across Europe to test the 
readability of the mandatory leaflets for patients included in every medicine pack (5). 
Such user testing has also been used to test a wide range of lay health information, 
including clinical trial informed consent forms (ICFs) (6). In particular, it has also 
been used to test other regulatory lay summaries: 
x the European Public Assessment Report (EPAR) summary (8) 
x the Risk Management Plan (RMP) summary (9)  
The objective of this study was to DSSO\µXVHUWHVWLQJ¶WRmaximise the readability and 
DFFHSWDELOLW\RIDµClinical Trial Results Laypersons Summary¶, to determine whether 
it meets OD\SHRSOH¶VQHHGV, including those with a range of health literacy levels. 
The findings were intended to inform the above public consultation on the summaries 
(3). 
 
METHODS 
We tested a sample OD\SHUVRQV¶summary based on the results of a previously 
completed clinical trialµA Multi-Center, Double-blind, Randomized, Parallel-Group 
Study Investigating the Effect of Montelukast in Patients With Seasonal Allergic 
Rhinitis - Spring 2001 Study¶(10). The summary was prepared before the draft 
guidance was released, but after the µelements¶ZHUHavailable in the Regulation. 
However, for headings, we replaced this wording with lay friendly headings (see 
Table 1 and additional explanatory text in Materials Tested below). The summary 
was tested on a computer screen. 
User testing tests the usability of both content and structure in a written material 
using mixed methods: 
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x quantitative questioning: can the reader find key pieces of information and 
express the information in their own words?  
x qualitative questioning ± this augments the quantitative data, giving insights into 
WKHSRVLWLYHDQGQHJDWLYHDVSHFWVRIWKHLQIRUPDWLRQIURPWKHSDUWLFLSDQW¶V
perspective.  
Use testing is a diagnostic process which can identify problems with information 
content and design using small samples. In line with the iterative nature of user 
testing, the principles of good information writing and design were applied, in a 
formative, iterative way, to identify and rectify readability problems within information 
(5), along with recommendations from the subsequently released draft guidance for 
consultation. 8VHUWHVWLQJGLIIHUVVLJQLILFDQWO\IURPWKHXVHRIµUHDGDELOLW\
IRUPXODH¶VXFKDV602*DQG)OHVFK7KHVHDUHEDVHGRQZRUGDQGVHQWHQFH
length only ± a very small part of the totality of influences on readability. 
 
Participants  
Participants were members of the general public - the target group for the summary - 
recruited from the database of Luto Research, the company which undertook the 
user-testing interviews.  The database draws on people in the Leeds area of the 
North of England, and comprises people who have volunteered to take part in the 
testing of health information materials. The main exclusion criteria were people 
who have taken part in a user test in the previous 6 months and those with a 
health professional or pharmaceutical background. 
Each round of user testing interviews was intended to include at least ten 
participants, across different genders, age groups and educational backgrounds (up 
WR%DFKHORU¶VGHJUHHOHYHO and computer confidence. Computer confidence was 
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self-reported by participants in answer to a question about how confident they 
were when using computers (very confident, quite confident, or not confident). 
To ensure we had a range of levels of health litHUDF\LQWKLVµFRUH¶JURXSZH
DVVHVVHGWKLVXVLQJDYDOLGDWHG8.YHUVLRQRIWKH³1HZHVW9LWDO6LJQ´which 
measures text and numerical literacy. This measure was chosen because of its 
acceptability and ease of application compared to other methods (11) (NVS ± 
see Appendix A). We aimed to recruit participants across a range of health literacy 
levels as follows: 
x between RUSDUWLFLSDQWVµORZ¶- a score of 0 or 1  
x between RUSDUWLFLSDQWVµLQWHUPHGLDWH¶- a score of 2 or 3 
x the remainder with a score of 4 or above on the UK NVS µDGHTXDWH¶ 
A total of 13 participants were recruited to the core group in Round 1 of testing so as 
WRPHHWWKHTXRWDRISDUWLFLSDQWVZLWK³ORZ´KHDOWKOLWHUDF\In Round 2, the quota was 
met with the first ten participants, so additional participants were not recruited. 
We also wanted feedback from participants who had undergone higher education. 
This means WKDWDVZHOODVWKHµFRUH¶JURXSZHLQFOXGHGDQDGGLWLRQDOµKLJKHU
education¶+(JURXS of four participants in each round of testing. The criteria for 
this was having a masters, doctorate or equivalent (all of whom had adequate 
health literacy). 
A new cohort of participants was used in the second round of testing, to prevent a 
learning effect. Summary demographics for age, gender, education level, use of 
literature, health literacy level and computer confidence were matched as far as 
possible across Round 1 and Round 2 of testing.  
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Materials tested 
Round 1 
In the sample summary tested, the headings (or µelements¶) included in the EU 
Regulation were replaced with lay friendly headings instead of the terminology 
proposed (see Table 1). This was because non lay-friendly technical wording such 
DVµ,QGLFDWLRQLIIROORZXSWULDOVDUHIRUHVHHQ¶ in headings has been shown to be 
detrimental to readability, particularly for people with low to average reading skills 
(8,9).  
Also, it was agreed that the summary would be anonymized and all identifying 
information would be removed e.g. SURGXFWQDPHVUHSODFHGZLWK³0HGLFLQH$´etc. 
The summary tested in Round 1 is shown in Figure 1. 
In accordance with good practice (12,13), and taking account of the information 
being presented on screen, we formatted the original summary to include:  
x sub-headings 
x blue banded main headings in larger text 
x bullet points 
x bolding  
x white space. 
Round 2 
Following the first round of testing, a number of improvements to the summary were 
agreed, based on: 
x Results from the quantitative testing in Round 1 i.e. where problems in finding or 
understanding points of information were identified 
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x Comments from participants given during the qualitative feedback section in 
Round 1 
x Recommendations from the subsequently published consultation document from 
the Commission  
x Good practice in information writing and design. 
The resulting revised summary tested in Round 2 is shown in Figure 2. 
Procedure 
Participants were interviewed individually and the summary was presented on a 
computer screen ± how the summaries will be available on the EMA website. Each 
participant was given time to read the document at their own pace.  
The 12 key points of information for testing were agreed by all team members and a 
questionnaire devised to evaluate these points (see Appendix B). The questionnaire 
DQGOHDIOHWZHUHSLORWWHVWHGZLWKWZRSHRSOHIURPD³FRQYHQLHQFHVDPSOH´, following 
which 2 questions were removed (as the interview was over-long), and 2 questions 
were re-worded for clarity.  
The questionnaire was split into two main parts: 
x quantitative section ± with questions designed to determine whether information 
could be found and understood.  
x qualitative section ± to elicit feedback on participants¶ views of the document; 
what they may have found easy or difficult. In addition, we asked a number of 
targeted questions about the VXPPDU\¶Vintended audience, usefulness to the 
public and why it was written (see also Appendix B). 
For the quantitative questions, the success criteria in current European guidance for 
patient leaflets (13) were used as a guide: 
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x 90% of participants tested should be able to find the information in the summary 
x 90% of participants who found the information should also be able to understand 
it. 
µ,QGLFDWLYHDQVZHUV¶ZHUHGHYHORSHGWRHQVXUHFonsistent scoring for each question. 
The interviewer noted whether the participant had any difficulty finding each piece of 
information (defined as taking more than two minutes to find the information or 
needing PRUHWKDQWZR³SHUPLWWHGSURPSWV´VXFKDVUHSHDWLQJWKHTXHVWLRQ).  
The responses to the qualitative questions were recorded and transcribed verbatim. 
We looked for recurring patterns of comments and chose quotes which illustrated 
these points.  
The study was reviewed and approved by the University of Leeds, School of 
Healthcare Research Ethics Committee (HREC15-054). Each participant was paid 
£30 for travel and other expenses. 
 
RESULTS  
31 participants were interviewed in 2 rounds: 
x Round 1: 13 µcore¶SDUWLFLSDQWV plus 4 higher education (HE) participants 
x Round 2: 10 µcore¶ plus 4 HE participants 
Participant demographics are described in Table 2. 
 
(Table 2 Here) 
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Round 1  
Quantitative findings 
In the core group, 11 of the 12 items of information from the summary passed the 
user testing criteria in Round 1. That is, at least 90% of participants were able to find 
each item of information and of these, at least 90% understood it correctly. Again, in 
the HE group, 11 of the 12 items of information passed the user testing criteria in 
Round 1. Note that the items that did not meet the criteria differed between the core 
group and the HE group (Core group: Q11; HE group: Q1) ± both are discussed 
below along with other questions that participants found more difficult to answer.  
(a) Questions that did not meet the test criteria  
Q11 ³)RUWKLVTXHVWLRQ,¶GOLNH\RXWRWKLQNDERXWWKHSDWLHQWVZKRKDG0HGLFLQH$
and Medicine B. After the study, how did they feel overall about their seasonal 
DOOHUJLHV"´ 
± Core group: 
o 3 found with difficulty (Health Literacy: 2 intermediate; 1 adequate);  
o 3 unable to find (HL: 2 intermediate; 1 adequate);  
o 2 not understood (HL: 1 low; 1 intermediate).  
± HE group:  
o 1 found with difficulty (HL: adequate) 
Participants appeared distracted by technical descriptions of the study measures e.g. 
³3DWLHQW¶V*OREDOEvaluation of Seasonal Allergy Symptoms´$OVRUHDGHUVJHQHUDOO\
focus on information presented first on a bullet point. Hence the order of information 
on the bullets were swapped - with the lay description first and technical term after in 
inverted commas. 
Q1 ³:KDWZHUHWKHWZRPDLQSXUSRVHVRIWKHVWXG\"´  
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± Core group:  
o 1 unable to find (HL: 1 low);  
o 1 not understood (HL: 1 low).  
± HE group:  
o 1 unable to find (HL: adequate) 
Following Round 1, tKHVWUXFWXUHDQGIRUPDWRILQIRUPDWLRQXQGHU³:K\ZDVWKis 
VWXG\GRQH"´ZDVtherefore refined, as the overall purposes of the study may have 
been lost in this relatively long section of information. In addition, a bolded 
LQWURGXFWLRQWRHDFKSXUSRVHZDVDGGHGDWWKHVWDUWRIHDFKEXOOHWSRLQW³To look at 
daytime nose V\PSWRPV´DQG³TRORRNDWVDIHW\´- to clarify that these were the main 
points. Also, extraneous information that was not directly related to the purpose of 
the study was moved to elsewhere in the document. This was intended to help to 
focus WKHUHDGHU¶VDWWHQWLRQRQWKHWZRSXUSRVHVRIWKHVWXG\UDWKHUWKDQRWKHU
related information. See Table 3.  
(Table 3 here) 
(b) Questions that were more difficult to answer 
Q7 ³How did the change in daytime nose symptoms compare in the three groups 
after two ZHHNV"´ 
- Core group:  
o 2 found with difficulty (HL: 1 intermediate; 1 adequate),  
o 1 unable to find (HL: 1 intermediate). 
- HE group:  
o no negative scores 
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Following Round 1, several changes were made as a result to the presentation of 
LQIRUPDWLRQXQGHU³What ZHUHWKHUHVXOWVRIWKHVWXG\"´. The original sub-headings 
ZHUH³Primary finding´DQG³Other findings´,WZDVFRQVLGHUHG³3ULPDU\ILQGLQJ´
would not be understood by many lay people not familiar with research. The sub-
headings were therefore refined to foFXVRQWKHV\PSWRPVLH³Daytime nose 
symptoms´DQG³Other symptoms´ 
Q12 ³+RZGLGUHVHDUFKHUVILQGRXWDERXWSDWLHQWV¶V\PSWRPVZKLOHWKH\ZHUHLQWKH
VWXG\"´ 
- Core group:  
o 2 found with difficulty (HL: 1 intermediate, 1 adequate) 
o 1 unable to find (HL: 1 intermediate)  
- HE group:  
o no negative scores 
Following Round 1, the sub-heading for this information was simplified and re-
RUGHUHGWRIRFXVRQ³V\PSWRPV´Additionally, the information under this sub-heading 
was split into two more distinct sections of information and bold text was added at 
the start of each paragraph to draw the reader to the information, this included 
³'LDU\´DQG³3DWLHQWV¶VFRUHV´ 
The full set of quantitative findings are presented in Table 4. 
 
(Table 4 here)
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Qualitative findings 
As part of  Round 1, participants were asked to provide feedback in terms of their 
impressions of the leaflet. In general, the language was well received. As expected, 
those with lower health literacy generally showed more difficulty with the words.  
³,IRXQGLWVWUDLJKWIRUZDUG,FRXOGXQGHUVWDQGHYHU\WKLQJWKURXJKWKDWDSDUWIURP
VRPHRIWKHZRUGV,FRXOGQ¶WSURQRXQFHWKHP´Core group; Low HL) 
People liked the use of colour and bold text for the main section headings. One said 
³the blue headings) SURMHFWHGWKHDUHDVWKDW\RXQHHGHDVLHU´ Others also 
commented on the wording of the headings: ³It has sensible sub-titles in between the 
EOXHEDQQHUVVRµ:K\ZDVWKHVWXG\GRQH"¶µ+RZZDVWKHVWXG\Gone?¶´ 
As participants in this study viewed the information on screen, the blue banding all 
across the page helped them to see clearly that they were in a new section as they 
scrolled down: ³It was quite easy (to find information). Because you can scroll down 
DQGZLWKWKHEOXHKHDGLQJDVZHOO>«@WKDW¶VYHU\KHOSIXO´ 
Findings from the targeted questions asked at the end of the qualitative questions 
have been combined and presented at the end of this section. 
Revising the summary after Round 1 
Following the first round of testing, the changes described above were made. In 
addition a number of further improvements were agreed based on: 
x Guidance in the consultation document  
x Good practice in information writing and design.   
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General format changes 
x To reduce overall line length, margins were widened on left and right - a shorter 
line length is more readable, particularly for people with low health literacy.  
x Guidance says not to use long and complex sentences ± so for long sentences 
we either split them into two smaller sentences, or used a hyphen within the 
sentence, to separate the information into manageable chunks. For example: 
Tested wording (Round 1) Tested wording (Round 2) 
To see how well a drug called 
Medicine A could improve symptoms 
of seasonal allergies (seasonal 
DOOHUJLFUKLQLWLVFRPSDUHGWRD³VXJDU
SLOO´WKDWGLGQ¶WFRQWDLQDQ\GUXJ
(placebo). 
To see how well a drug called 
³0HGLFLQH A´ could improve 
symptoms of seasonal allergies 
(seasonal allergic rhinitis). This was 
FRPSDUHGWRD³VXJDUSLOO´WKDWGLGQ¶W
contain any drug (placebo). 
x Guidance VD\VWR³UHPRYHXQQHFHVVDU\ZRUGV´- we identified such words and 
phrases and removed them, for example:  
Tested wording (Round 1) Tested wording (Round 2) 
1 out of every 10 people (10%) of the 
ZRUOG¶VSRSXODWLRQ 
1 out of every 10 people (10%) in the 
world 
x We found that information about the doses was included twice. This information 
ZDVWKHUHIRUHUHPRYHGXQGHU³+RZZDVWKLVVWXG\GRQH"´ 
x The opening section was amended to give more prominence to the lay title - by 
increasing the font size and using a bold font. Also, the prominence of the 
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numbers and references that identify the trial was reduced - in line with draft 
JXLGDQFHWR³DYRLGRYHUZKHOPLQJWKHUHDGHUZLWKWRRPXFKLQIRUPDWLRQ´ 
x New sub-KHDGLQJVZHUHDGGHGXQGHU³:KDWVLGHHIIHFWVGLGSDWLHQWVKDYH? - in 
line with the guidance recommendation on the use of sub-headings to organize 
information.  
x One participant would have liked to have seen section numbers in the summary ± 
and this has been found helpful in the user testing of other lay summaries.  
³7KHSDJHVDUHQXPEHUHGEXWWKHVHFWLRQVDUHQRW³:KRWRRNSDUWLQWKH
VWXG\´WKDWFRXOGKDYHEHHQQXPEHUWKUHHRUVRPHWKLQJ´ (Core group; 
Intermediate HL) 
However, as the comment was from only one participant this was not 
implemented and an additional question added to the questionnaire for Round 2.   
Chart LQµ:KDWZHUHWKHUHVXOWVRIWKHVWXG\¶ (see Figure 1) 
During Round 1, several core group participants described the chart DV³confusing´RU
³too simple´DQGWKDWLW³means nothing´However, some did say they found the chart 
clear and helpful. There were two main themes in the comments: 
- Numbers, figures, axis labels: 
³7KHUH¶VQRQXPEHUVVRLW¶VKDUGWRNQRZZKHWKHUDVPDOOHUEDULQLWLDOO\ORRNLQJ
DWLWLVDJRRGRUDEDGWKLQJ´ (HE group; Adequate HL) 
- Bars below axis:  
³,RQO\XQGHUVWRRGLWZKen I read text underneath. It looked a bit random with the 
EODFNOLQHDWWKHWRS´ (HE group; Adequate HL) 
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 One of the participants in the pilot test had also commented that the chart looked 
³upside-down´ 
Hence, the main change implemented following Round 1 was the direction of the 
bars was reversed - so an improvement in symptoms was shown as a bar above the 
horizontal axis line, rather than below. The updated chart is shown in Figure 2. 
Alternative versions of the chart were also created (see Appendix C) and feedback 
obtained in Round 2.   
Round 2: revised version  
Quantitative findings 
In the core group, 10 of the 12 items of information from the summary passed the 
user testing criteria in Round 2. Performance on the two questions that had not met 
the criteria in the first round (Q1 and Q11) was improved, but there was difficulty 
instead with two different questions (Q 8 and Q12). Suggestions to improve the 
summary further were discussed. All 12 items passed the user testing criteria in the 
HE group in Round 2. 
(a) Questions where performance was improved in Round 2 
Q11 ³)RUWKLVTXHVWLRQ,¶GOLNH\RXWRWKLQNDERXWWKHSDWLHQWVZKRKDG0HGLFLQH$
and Medicine B. After the study, how did they feel overall about their seasonal 
DOOHUJLHV"´ 
- This question met the test criteria in Round 2 across both core and HE groups.  
Q1 ³:KDWZHUHWKHWZRPDLQSXUSRVHVRIWKHVWXG\"´ 
- All participants in Round 2 were able to find and understand this information 
following amendments implemented between rounds..  
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(b) Questions that did not meet the test criteria (Round 2) and improvements 
Q8 ³7RWDNHSDUWLQWKHVWXG\KRZORQJPXVWSHRSOHKDYHKDGVHDVRQDODOOHUJLHVIRU"  
- Core group:  
o 2 found with difficulty (HL: 2 intermediate) 
o 2 unable to find (HL: 1 low, 1 intermediate) 
- HE group:  
o no negative scores 
Examination of the data showed that participants seemed unable to identify this 
information in the text, possibly because it LV³KLGGHQ´DWWKHHQGRIDEXOOHWSRLQW (as 
described above). Hence ³VHDVRQDODOOHUJLHV´were re-positioned at the start of the 
bullet in the final version. 
Tested wording Final wording 
x +DYHDGRFWRUVD\WKDWWKH\¶YHKDG
seasonal allergies for 2 years or more  
x Have had seasonal allergies for 2 
years or more (confirmed by a 
doctor) 
Q12 ³+RZGLGWKHUHVHDUFKHUVILQGRXWDERXWSDWLHQWV¶V\PSWRPVZKLOHWKH\ZHUHLQ
WKHVWXG\"´ 
- Core group:  
o 2 found with difficulty (HL: 1 low, 1 intermediate) 
o 3 unable to find (HL: 1 low, 2 intermediate) 
- HE group: 
o 2 found with difficulty (HL: 2 adequate). 
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The sub-heading for this section was amended after Round 1 to make it simpler and 
WRIRFXVRQ³V\PSWRPV´VHHPLGGOHZRUGLQJEHORZ$VXJJHVWHGIXUWKHUDPHQGPHQW
to the heading is shown below on the right.  
Round 1 heading Round 2 heading Suggested final heading 
+RZGLGUHVHDUFKHUV
PHDVXUHV\PSWRPV" 
+RZZHUHV\PSWRPV
PHDVXUHG" 
+RZZHUHV\PSWRPV
PHDVXUHGE\UHVHDUFKHUV" 
The final version of the summary is provided in Figure 3. 
 
Qualitative findings - targeted questions 
After the general qualitative questions, the following targeted questions were asked:  
x Who do you think this summary has been written for? 
Across both rounds, most were not aware that this document was intended for the 
general public. Only 12 / 31 (39%) mentioned patients / general public / lay 
people. 
Others referred to included doctors, the drug company or researchers. That the 
document is for lay people is not explicitly stated in the document (in line with the 
current guidance) so it is unsurprising that participants gave varied answers.  
x How useful do you think the information in the summary would be to 
members of the public? 
There was a general consensus that the information would be useful if you were 
thinking of taking the study medicines or if you had seasonal allergies. However, 
responses about usefulness to the wider public varied.  
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³7KLVZRQ¶WDFWXDOO\DIIHFWSDUWRIWKHSXEOLF,W¶VRQO\JRLQJWRDIIHFWWKH
SHRSOHZKRDSSOLHGWRKHOSRXWRQWKHVWXG\´(Core group; low HL) 
³,FDQ¶Wimagine a member of the public wanting to know this unless they 
were particularly interested in the process of drug creation or the studies 
EHKLQGLW´ (HE group; Adequate HL) 
x Why do you think this summary has been written? 
Those that referred to the purpose of the summary gave a variety of responses, 
for example: 
³,KDYHQRLGHDDFWXDOO\>«@'RWKHVHVWXGLHVFRPHRXWLQWRWKHSXEOLF
DUHQD",GRQ¶WNQRZ,ZRXOGKDYHWKRXJKWLWZRXOGKDYHMXVWVWD\HGLQWKH
PHGLFDOSURIHVVLRQ´ (Core group; Intermediate HL) 
³7RUHVHDUFKLWDQGVRLWFDQEHJLYHQRXWWRWKHSXEOLF>«@\RXQHHG
YROXQWHHUVGRQ¶W\RXWRKHOSZLWKWKHUHVHDUFK´ (Core group; Intermediate HL) 
x This summary tells you about the results from one study - other studies 
may show different results. How clearly was this described in the 
document? 
We used the wording suggested in the guidance³This summary only shows the 
results from this one study. Other studies may find different results´. However, 
across both rounds, 20 / 31 (65%) participants either did not recall this information 
or did not think that this was highlighted enough in the document. 
As described above, another version of the summary with section numbers on each 
of the main section headings was shown to participants and the following question 
asked during Round 2 only.  
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x Tell me whether you prefer the headings with or without numbers and why? 
In the core group, 8 / 10 participants (80%) preferred the numbered headings. In 
the HE group, all 4 participants (100%) did not think the numbers were needed. 
Those that preferred the version with numbers gave reasons such as: 
³EHFDXVHLWPDNHVLWVWDQGRXWWRPH´ (Core group; Adequate HL) 
³EHFDXVH\RXNQRZWKH\¶UHVHSDUDWHSDUDJUDSKV´ (Core group; Adequate HL) 
Following testing, it was agreed that numbered headings should be incorporated 
into the summary to aid readers. This is shown in the final version of the summary 
in Figure 3. 
x What is your view on the reading level of the document - did it seem 
appropriate to you? 
This was asked to the HE group only. All eight of the HE participants found the 
language to be acceptable and remarked positively on the words used:  
³,WZDVDSSURSULDWHIRUWKHPDMRULW\RIWKHSRSXODWLRQ,WZDVILQHIRUPH´  
³,WVHHPV DERXWULJKW<RX¶YHJRWWKHULJKWEDODQFHWKHULJKWWHUPLQRORJ\´  
x Looking at the chart showing you the results, what were your views on the 
chart? What do you think it is telling you? 
Feedback from Round 1 was used to inform the development of alternative chart 
formats, one of which was included in the version tested in Round 2. Three other 
versions were shown to the participant at the end of testing. The four alternative 
chart formats are shown in Appendix C, along with the feedback for these 
alternatives: Most participants (9 / 14; 64%) across both groups in Round 2 
21 
 
preferred the chart included in the main body of the summary and were generally 
able to describe what the chart is showing to a good degree of understanding.  
DISCUSSION  
Main findings 
The development of the final version of this clinical trial laySHUVRQ¶VVXPPDU\ was 
informed by the draft guidance on writing such summaries and then testing using the 
PHWKRGRIµXVHUWHVWLQJ¶ with the target audience. The user testing process showed 
that it is possible to create a largely health literate summary for most people 
across a range of backgrounds. However, it has also highlighted areas within the 
summary that could be improved to increase the readability.  
Notably, the majority of participants were unaware that the summary was intended 
for the general public ± they suggested a wide range of other audiences. The 
summary therefore needs an introductory section that makes it clear to the reader 
who it has been written for and why it has been written (not present in the current 
draft guidance). Such an introduction has been found useful for readers in testing of 
EPAR and RMP summaries (8,9) and should be included in all clinical trial 
summaries.  
Readers must understand that the results are only from one study and that other 
studies may have different results. The single sentence from the draft guidance was 
included in the tested summary, but the majority in both rounds did not recall this 
information or thought it was not clear or highlighted enough in the document. More 
prominence is needed to emphasizHWKDWµ2WKHUVWXGLHVPD\VKRZGLIIHUHQWUHVXOWV¶
by the use of an additional sub-heading and adding more detail to emphasize its 
importance. 
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In more general terms, the user feedback and the consideration of good practice 
showed that improvements were needed to both the content of the information (the 
words used), and the design of the original summary. This is because people had 
problems finding as well as understanding information. These findings which can 
guide the preparation of such summaries in the future are summarized in the 
Recommendations in Table 5.  
People with higher education 
All readers, including those with higher education qualifications, appreciated the clear 
and straight forward language used in the tested summary. That the participants with 
higher education qualifications were positive about the revised summary is important. 
This is because, anecdotally, some argue that writing in straightforward plain 
language will not be acceptable to those with higher educational backgrounds - given 
that they may be used to reading more technical or complicated information.  
Charts and graphs 
A number of participants had difficulty with the chart, one thinking WKDWLWZDVµupside-
GRZQ¶. Members of the public not familiar with charts or graphs may be confused by 
numbers or the presentation of a graph if it is too technical. Any chart or graph should 
be supported by a simple description of what it is showing, and numbers or scales 
included only if they are simple to understand. Discussing or testing any chart or 
graph with lay readers will provide valuable feedback on whether the graph is 
effective.  
(Table 5 here)  
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There is a general learning that when presenting the main aims or purpose of a 
study, the summary wording should be concise and not contain too much additional 
information as this may distract from the overall purpose. 
Limitations 
User testing uses small sample sizes, but this is commensurate with a 
diagnostic approach. It is recommended by the European Medicines Agency, and 
extensive experience across Europe has shown that it can be useful in identifying 
problems with information using only small numbers.  
One limitation is that these findings arise from the testing of one example summary, 
and further testing of other summaries would be beneficial, particularly as experience 
develops. However, much of what we have found has general applicability across all 
W\SHVRIWULDOV$IXUWKHUOLPLWDWLRQLVWKDWWKHKHDGLQJVRUµHOHPHQWV¶DVWKH\DUH
described in the Regulation) are described as not being able to be changed. An 
H[DPSOHRIWKHZRUGLQJLVµInvestigational medicinal products used¶ Our findings 
depend on lay-friendly wording of these headings being used ± a way around this 
needs to be found. 
The testing was undertaken with participants reading the information on a 
screen ± as the summaries will be made available on the EMA website. Most of 
the findings could be applied to paper-based versions of such summaries, as 
they relate to the text ± however any layout and design aspects would need to 
be tested on paper. 
Relationship with wider literature 
The summaries of clinical trials being considered here are a new concept, being 
addressed to the general public. Such summaries designed for people who have 
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taken part in a clinical trial have been available for some time. However, these are 
not routinely produced and there have been calls in the United States for them to be 
widely available (14). It is noteworthy that some participants in this study questioned 
the usefulness of such summaries to members of the general public. 
This user testing follows on from such testing on other lay summaries required in the 
EU. Testing of a lay summary of a European Public Assessment Report (EPAR) was 
undertaken in 2013 and it found that people had difficulties finding and understanding 
key messages (8). Subsequently, testing of a summary of the Risk Management Plan 
found similar problems, notably non-lay friendly lay headings, complex tables, and a 
lack understanding of who the summary was written for (9). The European Medicines 
Agency have subsequently positively responded to these findings for both 
documents.  
7KHUHKDVEHHQDZLGHUGLVFRXUVHRQWKHFRQFHSWRIµWUDQVSDUHQF\¶DQGKRZLW is 
being applied in the context of medicines regulation in the EU. Way et al suggested 
WKDWµby focusing transparency policies on the full disclosure of regulatory information, 
EMA has inadvertently ignored the complexities of communicating to patients¶. They 
go on to describe the danger of µdecontextualized and complicated medicines 
infoUPDWLRQ¶DQGWKDWLWµwill decrease rather than increase their confidence in taking 
their medLFLQHV¶ (15) This emphasizes the need for all lay summaries to be clearly 
contextualized and described in non-complicated language. This study, through the 
PHWKRGRORJ\RIµXVHUWHVWLQJ¶KDVLGHQWLILHGZD\VLQZKLFKVXFKKHDOWKOLWHUDWH
summaries can be produced.   
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